SCHEMBL3769924

SCHEMBL3769924

O=C(O)Cc1ccc(-c2c[nH]c3ncc(-c4cccc5ccccc45)cc23)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 7/20 0.76
CDK2 P24941 2/20 0.57
CCNT1 O60563 1/20 0.57
CCNA2 P20248 1/20 0.57
CDK9 P50750 1/20 0.57
AXL P30530 6/20 0.55
CAMKK2 Q96RR4 3/20 0.55
MAP3K11 Q16584 1/20 0.54
CDC7 O00311 1/20 0.53
PLK4 O00444 1/20 0.53
CHEK1 O14757 1/20 0.53
AURKA O14965 1/20 0.53
MAPK13 O15264 1/20 0.53
PDPK1 O15530 1/20 0.53
DYRK3 O43781 1/20 0.53
ROCK2 O75116 1/20 0.53
RPS6KA5 O75582 1/20 0.53
PRKD3 O94806 1/20 0.53
PAK4 O96013 1/20 0.53
CHEK2 O96017 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3763815 0.90 SGK1 (0.61) SGK1CDK2CCNT1CCNA2CDK9
SCHEMBL3764153 0.87 SGK1 (0.63) SGK1CDK2AXLCAMKK2MAP3K11
SCHEMBL3769483 0.86 SGK1 (1.00) SGK1CDK2AXLCAMKK2MAP3K11
SCHEMBL3768795 0.86 AXL (0.74) SGK1CDK2CCNT1CCNA2CDK9
SCHEMBL3772598 0.85 SGK1 (0.82) SGK1CDK2AXLCAMKK2MAP3K11
SCHEMBL3762345 0.84 SGK1 (0.65) SGK1CDK2AXLCAMKK2MAP3K11
SCHEMBL3771182 0.84 SGK1 (0.65) SGK1CDK2AXLCAMKK2MAP3K11
SCHEMBL3755777 0.82 SGK1 (0.66) SGK1CDK2AXLCAMKK2MAP3K11
SCHEMBL3763745 0.81 AXL (0.77) SGK1CDK2CCNT1CCNA2CDK9
SCHEMBL3765153 0.81 NTRK1 (0.73) SGK1CDK2AXLCAMKK2CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US claimed
WO-2010049173-A1 USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES CENIX BIOSCIENCE GMBH (DE) 2010-05-06 WO claimed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US claimed
EP-1828180-A1 1H-PYRROLO[2,3-BETA]PYRIDINES SMITHKLINE BEECHAM CORPORATION (US) 2007-09-05 EP claimed
WO-2006063167-A1 1H-PYRROLO[2,3-B]PYRIDINES SMITHKLINE BEECHAM CORPORATION (US) 2006-06-15 WO claimed
WO-2021006707-A1 USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES 한양대학교 산학협력단 2021-01-14 WO disclosed
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines GlaxoSmithKline, LLC 2012-09-20 US disclosed
WO-2010049173-A1 USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES CENIX BIOSCIENCE GMBH (DE) 2010-05-06 WO disclosed
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes GLAXOSMITHKLINE LLC 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233955-A1 1H-Pyrrolo[2,3-B]Pyridnes SGK1, SGK2, SGK3 SGK1 1/4885CDK2 281/4885CCNT1 1339/4885
US-20120238588-A1 1H-Pyrrolo[2,3-B]Pyridines SGK1, SGK2, SGK3 SGK1 1/4885CDK2 315/4885CCNT1 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.